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ABSTRACT 
Ophthalmic application of a non-selective beta blocker like timolol maleate is known to produce bronchoconstriction in asthmatic individuals or 
patients with obstructive lung diseases. Timolol-induced bronchoconstriction in a previously healthy young adult without any pulmonary disease is 
rare. We report a case of a young adult who developed bronchoconstriction following ocular instillation of timolol maleate ophthalmic solution 
when he was treated for open-angle glaucoma. 
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Timolol, a non-selective beta-adrenergic blocker is commonly used 
as an ophthalmic solution for the treatment of glaucoma. It blocks 
the beta adrenergic receptor in the ciliary body, resulting in the 
reduction of aqueous humour formation, by decreasing cyclic 
adenosine monophosphate (cAMP). It possesses the therapeutic 
advantage of lowering intraocular pressure without changing the 
pupillary size or causing a diminution of vision and has no 
significant intrinsic sympathomimetic, direct myocardial depressant 
or local anesthetic (membrane-stabilizing) activity [1]. 
Timolol ophthalmic administration into conjunctiva will drain down 
the nasopharyngeal mucosa through nasolacrimal duct to the 
systemic circulation, bypass the liver, where it is normally 
metabolized [1]. Here, we present a case of timolol-induced 
bronchospasm in a patient without a history of respiratory disorders 
and resolved following drug withdrawal.  
CASE REPORT 
A 36-year-old male farmer (consent obtained from the patient for 
publication of case report) was admitted with a history of high-grade, 
intermittent fever, and conjunctival congestion. There was no previous 
history of bronchial asthma or exertional breathlessness. He was not a 
smoker. There was no family history of bronchial asthma. Physical 
examination of the patient showed conjunctival suffusion with 
subconjunctival hemorrhage. Respiratory system examination was 
normal. His laboratory parameters during admission were normal, 
except for leukocytosis (14,600 cells/cu. mm). His chest x-ray showed 
prominent perihilar broncho vascular markings.  
In view of conjunctival suffusion and hemorrhage, an ophthalmology 
consultation was sought for. The evaluation showed raised 
intraocular pressure and patient was diagnosed to have primary 
open angle glaucoma. He was prescribed a combination of 
brimonidine with 0.5% timolol ophthalmic solution, to be instilled 
twice a day. The patient was also started on piperacillin-tazobactam 
with doxycycline as empirical therapy for leptospirosis, pending 
serology.  
The patient developed a dry cough on the 3rd day after starting 
timolol eye drops. Auscultation of the chest revealed bilateral 
polyphonic rhonchi. However, his fever and other systemic 
symptoms subsided. Repeat chest X-ray showed clearing of perihilar 
shadow. He was started on nebulised salbutamol and ipratropium 
bromide for his respiratory complaints. His cough is increased on 
subsequent days and rhonchi worsened. We worked up for the 
etiology of bronchospasm, however no known cause could be 
established. Timolol was discontinued and plain brimonidine (α2-
adrenergic receptor agonist) was continued. After discontinuation, 
the patient improved symptomatically, and rhonchi completely 
cleared up in 2 d. At follow-up after 2 w, the patient was 
asymptomatic and had a normal intraocular pressure.  
DISCUSSION 
Timolol has been found to cause bronchospasm based on a few 
reports documented previously, which were either in mild asthmatic 
patients or in healthy elderly individuals [2]. The present case is 
important to note because this young patient had no respiratory 
disorder during or prior to admission. He is neither a smoker nor 
does he give a history of bronchial asthma or bronchitis. In our case, 
timolol was found to be a “probable” cause of bronchoconstriction 
(based on Naranjo’s algorithm for causality). We did not rechallenge 
our patient with timolol as any other drug was found to be 
responsible for the bronchospasm and the temporal relationship 
between the timolol dose and the subsequent occurrence of cough 
strongly implicated timolol as the inciting agent. Also, rechallenge is 
not necessitated as bronchoconstriction could be potentially life-
threatening [3].  
Assessment of adverse drug reaction was performed by using 
Naranjo scale and Hartwig scale [4, 5]. According to the Naranjo 
scale, the adverse drug reaction was found to be “probable” (score of 
7 was obtained). As per Hartwig scale, it was moderately severe 
(level 4(a), i.e. adverse drug reaction requires the discontinuation of 
suspected drug, and treatment is required which increases the 
length of stay by at least one day). 
CONCLUSION 
The authors are reporting this case to stress on the fact that local use 
of a beta blocker even in non-asthmatic individuals can produce 
significant bronchoconstriction and hence, caution should be 
exercised even when using a topical beta blocker [6]. 
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